HCA

HCA Healthcare, Inc. (HCA) - Form 10-Q Summary

Business Context and Reporting Period

This summary covers the quarterly period ended June 30, 2026, and the six months ended on that date. HCA Healthcare, Inc. is a holding company operating 190 hospitals, 118 freestanding surgery centers, and 30 freestanding endoscopy centers across 19 U.S. states and England. The company operates through three geographic groups: National, Atlantic, and American.

Key Financial Metrics

Note: Operating cash flow for Q2 2026 is derived from the six-month total ($4.349B) minus Q1 2026 ($2.014B implied by the text's Q2 specific decline discussion, though the text explicitly states Q2 2026 operating cash flow was $2.335 billion).

Material Changes vs. Prior Period

• Revenue Growth: Consolidated revenues increased 8.7% in Q2 2026 compared to Q2 2025, driven by a 6.0% increase in revenue per equivalent admission and a 2.6% increase in equivalent admissions.
• Uncompensated Care: Total uncompensated care rose significantly to $15.076 billion in Q2 2026 from $11.625 billion in Q2 2025. Uninsured admissions increased 23.3% consolidated, attributed to the expiration of enhanced premium tax credits (EPTCs) at the end of 2025.
• Medicaid Impact: The company recognized $1.372 billion in incremental revenues and $829 million in related operating expenses in Q2 2026 due to the Florida directed payment program approved by CMS.
• Volume Trends: While emergency department visits increased 3.5%, inpatient surgical volumes declined 2.3% and outpatient surgical volumes declined 4.4% compared to the prior year quarter.
• Debt Structure: Total debt increased to $49.718 billion. In April 2026, HCA issued $3.0 billion in senior notes (due 2031, 2033, and 2036) and redeemed $2.5 billion in notes due in 2026.

Guidance, Outlook, and Risks

• Capital Expenditures: Planned capital expenditures for 2026 are expected to be between $5.0 billion and $5.5 billion, excluding acquisitions. Projects under construction have estimated additional costs of $8.6 billion over the next five years.
• Share Repurchases: The company repurchased 7.909 million shares in the first six months of 2026. As of June 30, 2026, $7.210 billion remained available under the January 2026 authorization.
• Dividends: A quarterly dividend of $0.78 per share was declared on July 23, 2026, payable September 30, 2026.
• Regulatory Risks: Management highlights risks related to the expiration of EPTCs, potential changes to Medicaid State Directed Payment (SDP) arrangements under the 2025 Federal Budget Act, and inflationary pressures on labor and supply costs.
• Liquidity: The company reported negative working capital of $122 million at June 30, 2026, primarily due to short-term borrowings. Excluding commercial paper, working capital would have been $3.768 billion. Management believes cash flows and credit facilities are sufficient for foreseeable needs.

Investor Verification Checklist

• Uninsured Admissions Trend: Verify the sustainability of the 23.3% increase in uninsured admissions and its long-term impact on net revenue per admission.
• Medicaid SDP Stability: Confirm the duration and renewal status of the Florida directed payment program and other state supplemental payments, given CMS regulatory changes.
• Operating Cash Flow Volatility: Investigate the $1.875 billion decline in Q2 operating cash flow compared to the prior year, driven by working capital changes and tax payments.
• Debt Refinancing: Monitor the company's ability to manage its $49.7 billion debt load amidst potential interest rate fluctuations and refinancing needs.
• Volume Mix Shifts: Assess the impact of declining surgical volumes (inpatient and outpatient) on future revenue growth despite rising admission counts.